Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod in Moderately to Severely Active Ulcerative Colitis – China Phase 3
CTR20221845Phase 3Terminated
- Sponsor
- Celgene Corporation
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ozanimod in autoimmune colitis, sponsored by Celgene Corporation. Started Jul 2022; status: terminated.
02
Drugs
ozanimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20221845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221845.